Baseline patient characteristics
| Baseline characteristics . | At initial diagnosis, n (%) . | Beyond initial diagnosis, n (%) . |
|---|---|---|
| Median months from diagnosis (range) | 1 (0-4) | 28* (5-296) |
| Median age, y (range) | 61 (24-83) | 65 (37-86) |
| Male sex | 84 (64) | 81 (65) |
| Zubrod performance status | ||
| 0 | 75 (57) | 52 (42)* |
| 1 | 51 (39) | 62 (50) |
| 2+ | 5 (4) | 11 (9) |
| JAK-2 positive | 21 of 39 (54) | 26 of 43 (60) |
| Prior hydroxyurea | 21 (16) | 51 (41)* |
| Prior alkylators/radiotherapy | 4 (3) | 10 (8) |
| Prior erythropoietin | 54 of 125 (43) | 73 of 120 (61)* |
| Prior androgen | 8 of 126 (6) | 9 of 120 (8) |
| Prior splenectomy | 2 (2) | 14 (11)* |
| Hemoglobin less than 10 g/dL or Tfn dependent | 58 (44) | 84 (67)* |
| White cell count less than 4 or more than 30 × 109/L | 35 (27) | 38 (30) |
| Platelet count less than 100 × 109/L | 35 (27) | 45 (36) |
| Monocytes 1.0 or more × 109/L | 22 (17) | 36 (29)* |
| Peripheral blasts 2% or more | 43 (33) | 54 (43) |
| Lactate dehydrogenase, IU/L: median (range) | 1228 (280-5101) | 1300 (301-10 353) |
| Lille score | ||
| 0 | 61 (47) | NC |
| 1 | 47 (36) | NC |
| 2 | 23 (18) | NC |
| Abnormal karyotype | 38 (29) | 53 (42)* |
| Baseline characteristics . | At initial diagnosis, n (%) . | Beyond initial diagnosis, n (%) . |
|---|---|---|
| Median months from diagnosis (range) | 1 (0-4) | 28* (5-296) |
| Median age, y (range) | 61 (24-83) | 65 (37-86) |
| Male sex | 84 (64) | 81 (65) |
| Zubrod performance status | ||
| 0 | 75 (57) | 52 (42)* |
| 1 | 51 (39) | 62 (50) |
| 2+ | 5 (4) | 11 (9) |
| JAK-2 positive | 21 of 39 (54) | 26 of 43 (60) |
| Prior hydroxyurea | 21 (16) | 51 (41)* |
| Prior alkylators/radiotherapy | 4 (3) | 10 (8) |
| Prior erythropoietin | 54 of 125 (43) | 73 of 120 (61)* |
| Prior androgen | 8 of 126 (6) | 9 of 120 (8) |
| Prior splenectomy | 2 (2) | 14 (11)* |
| Hemoglobin less than 10 g/dL or Tfn dependent | 58 (44) | 84 (67)* |
| White cell count less than 4 or more than 30 × 109/L | 35 (27) | 38 (30) |
| Platelet count less than 100 × 109/L | 35 (27) | 45 (36) |
| Monocytes 1.0 or more × 109/L | 22 (17) | 36 (29)* |
| Peripheral blasts 2% or more | 43 (33) | 54 (43) |
| Lactate dehydrogenase, IU/L: median (range) | 1228 (280-5101) | 1300 (301-10 353) |
| Lille score | ||
| 0 | 61 (47) | NC |
| 1 | 47 (36) | NC |
| 2 | 23 (18) | NC |
| Abnormal karyotype | 38 (29) | 53 (42)* |
One hundred thirty-one patients were evaluated within 4 months of initial diagnosis, and 125 patients were evaluated beyond initial diagnosis. Lille scores were calculated for those patients tested at initial diagnosis.
P < .05 between patients at initial diagnosis and beyond initial diagnosis.